Avanir Pharmaceuticals Inc. (AVNR) announced positive results from its phase II clinical trial of AVP-923, for the treatment of agitation in patients with Alzheimer's disease, Monday morning.
Avanir Pharmaceuticals gapped open dramatically higher Monday and is now up 2.98 at $9.72 on above average volume. The stock has surged to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News